Pre-existing Immunity to Endemic Human Coronaviruses Does Not Affect the Immune Response to SARS-CoV-2 Spike in a Murine Vaccination Model
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Endemic human coronaviruses (HCoVs) have been evidenced to be cross-reactive to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although a correlation exists between the immunological memory to HCoVs and coronavirus disease 2019 (COVID-19) severity, there is little experimental evidence for the effects of HCoV memory on the efficacy of COVID-19 vaccines. Here, we investigated the Ag-specific immune response to COVID-19 vaccines in the presence or absence of immunological memory against HCoV spike Ags in a mouse model. Pre-existing immunity against HCoV did not affect the COVID-19 vaccine-mediated humoral response with regard to Ag-specific total IgG and neutralizing Ab levels. The specific T cell response to the COVID-19 vaccine Ag was also unaltered, regardless of pre-exposure to HCoV spike Ags. Taken together, our data suggest that COVID-19 vaccines elicit comparable immunity regardless of immunological memory to spike of endemic HCoVs in a mouse model.
Abstract
Endemic human coronaviruses (HCoVs) have been evidenced to be cross-reactive to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although a correlation exists between the immunological memory to HCoVs and coronavirus disease 2019 (COVID-19) severity, there is little experimental evidence for the effects of HCoV memory on the efficacy of COVID-19 vaccines. Here, we investigated the Ag-specific immune response to COVID-19 vaccines in the presence or absence of immunological memory against HCoV spike Ags in a mouse model. Pre-existing immunity against HCoV did not affect the COVID-19 vaccine-mediated humoral response with regard to Ag-specific total IgG and neutralizing Ab levels. The specific T cell response to the COVID-19 vaccine Ag was also unaltered, regardless of pre-exposure to HCoV spike Ags. Taken together, our data suggest that COVID-19 vaccines elicit comparable immunity regardless of immunological memory to spike of endemic HCoVs in a mouse model.
참고문헌 (37)
- "Long COVID or post-COVID conditions"[URL]
- Anderson EM, "Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection", Cell, 184, pp.1858~1864 (2021)
- Manning J, "SARS-CoV-2 cross-reactivity in prepandemic serum from rural malaria-infected persons, Cambodia", Emerg Infect Dis, 28, pp.440~444 (2022)
- Sim KY, "Two opposing roles of SARS-CoV-2 RBD-reactive antibodies in pre-pandemic plasma samples from elderly people in ACE2-mediated pseudovirus infection", Front Immunol, 12, pp.813240~ (2022)
- Guo L, "Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients : a retrospective study", Emerg Microbes Infect, 10, pp.664~676 (2021)
- Lapp SA, "Original antigenic sin responses to betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection", PLoS One, 16, pp.e0256482~ (2021)
- Lin CY, "Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response", Cell Host Microbe, 30, pp.83~96 (2022)
- Yamaguchi T, "Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19", Int J Infect Dis, 109, pp.261~268 (2021)
- Loyal L, "Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination", Science, 374 (2021)
- Kundu R, "Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts", Nat Commun, 13, pp.80~ (2022)
- Abreu RB, "Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination", JCI Insight, 5, pp.e132155~ (2022)
- Elias G, "Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination", Elife, 11, pp.e68388~ (2022)
- Mongkolsapaya J, "Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever", Nat Med, 9, pp.921~927 (2003)
- Olson MR, "Competition within the virus-specific CD4 T-cell pool limits the T follicular helper response after influenza infection", Immunol Cell Biol, 94, pp.729~740 (2016)
- Johnson LR, "Epitope-specific vaccination limits clonal expansion of heterologous naive T cells during viral challenge", Cell Reports, 17, pp.636~644 (2016)
- Lee TY, "Outer membrane vesicle increases the efficacy of an influenza vaccine in a diet-induced obese mouse model", Immunol Lett, 219, pp.27~33 (2020)
- de Vries RD, "SARS-CoV-2-specific T-cells in unexposed humans : presence of cross-reactive memory cells does not equal protective immunity", Signal Transduct Target Ther, 5, pp.224~ (2020)
- Jacomy H, "Vacuolating encephalitis in mice infected by human coronavirus OC43", Virology, 315, pp.20~33 (2003)
- Liu DX, "Encyclopedia of Virology", pp.428~440 (2021), Academic Press
- Khoury DS, "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection", Nat Med, 27, pp.1205~1211 (2021)
- Steiner S, "HCoV-and SARS-CoV-2 cross-reactive T cells in CVID patients", Front Immunol, 11, pp.607918~ (2020)
- Johansson AM, "Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals", PLoS Pathog, 17, pp.e1010203~ (2021)
- Kutzler MA, "DNA vaccines : ready for prime time?", Nat Rev Genet, 9, pp.776~788 (2008)
- Wheatley AK, "Immune imprinting and SARS-CoV-2 vaccine design", Trends Immunol, 42, pp.956~959 (2021)
- Focosi D, "Previous humoral immunity to the endemic seasonal alphacoronaviruses NL63 and 229E is associated with worse clinical outcome in COVID-19 and suggests original antigenic sin", Life(Basel), 11, pp.298~ (2021)
- Aydillo T, "Immunological imprinting of the antibody response in COVID-19 patients", Nat Commun, 12, pp.3781~ (2021)
- Aguilar-Bretones M, "Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19", J Clin Invest, 131, pp.e150613~ (2021)
- Yamashita T, "Preexisting humoral immunity cross-reacting with SARS-CoV-2 might prevent death due to COVID-19 in critical patients", J Clin Med, 11, pp.3870~ (2022)
- Chalkias S, "A bivalent omicron-containing booster vaccine against COVID-19", N Engl J Med, 387, pp.1279~1291 (2022)
- Scheaffer SM, "Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the ba. 5 omicron variant in mice", Nat Med, 29, pp.247~257 (2023)
- Rehman MF, "Novel coronavirus disease(COVID-19)pandemic : a recent mini review", Comput Struct Biotechnol J, 19, pp.612~623 (2021)
- Grifoni A, "Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals", Cell, 181, pp.1489~1501 (2020)
- Howard FH, "Understanding immune responses to viruses-do underlying Th1", Th2 cell biases predict outcome?, 2022, pp.14, 1493~
- Jin H, "Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice", Biochem Biophys Res Commun, 328, pp.979~986 (2005)
- Fonseca DM, "Th1 polarized response induced by intramuscular DNA-HSP65 immunization is preserved in experimental atherosclerosis", Braz J Med Biol Res, 40, pp.1495~1504 (2007)
- Alamri SS, "Synthetic SARS-CoV-2 spike-based DNA vaccine elicits robust and long-lasting th1 humoral and cellular immunity in mice", Front Microbiol, 12, pp.727455~ (2021)
- Xie P, "A mouse-adapted model of HCoV-OC43 and its usage to the evaluation of antiviral drugs", Front Microbiol, 13, pp.845269~ (2022)